

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	. CONFIRMATION NO.
09/583,200	05/30/2000	John D Fikes	018623-015720US	1443
28393 75	590 09/11/2002			
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 NEW YORK AVENUE, NW SUITE 600			EXAMINER	
			SCHWADRON, RONALD B	
WASHINGTON, DC 20005-3934			ART UNIT	PAPER NUMBER
			1644	A 0
			DATE MAILED: 09/11/2002	12

Please find below and/or attached an Office communication concerning this application or proceeding.

licent/o)

Office Action Summary

Application No. 09/583,200

Applicant(s)

Fikes et al.

Examiner

Ron Schwadron, Ph.D.

Art Unit 1644



-	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address			
	for Reply				
THE N - Extensi mailing	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.				
- If NO p - Failure - Any rep	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the period term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. he application to become ABANDONED (35 U.S.C. § 133).			
Status					
1) 🗆	Responsive to communication(s) filed on	<u> </u>			
2a) 🗌	This action is FINAL . 2b)☐ This action	ion is non-final.			
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.				
	tion of Claims				
4) 💢	Claim(s) <u>1-36</u>	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
	Claim(s)				
	Claim(s)				
	Claim(s)				
		are subject to restriction and/or election requirement.			
	tion Papers				
9) 🗆	The specification is objected to by the Examiner.				
10) 🗌	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.			
	Applicant may not request that any objection to the di	rawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)	The proposed drawing correction filed on	is: a) □ approved b) □ disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t				
12)	The oath or declaration is objected to by the Examin	ner.			
_	under 35 U.S.C. §§ 119 and 120				
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)	☐ All b)☐ Some* c)☐ None of:				
1	1. Certified copies of the priority documents have	e been received.			
		re been received in Application No			
	 Copies of the certified copies of the priority do application from the International Burea 	ocuments have been received in this National Stage au (PCT Rule 17.2(a)).			
	ee the attached detailed Office action for a list of the				
_	a) The translation of the foreign language provisional application has been received.				
	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.			
Attachme	ent(s) tice of References Cited (PTO-892)				
	tice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s). 5) Notice of Informal Patent Application (PTO-152)			
	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	8) Other:			

Serial No. 09/583200 Art Unit 1644

- 1. Regarding peptides recited in the claims, it would expedite prosecution if applicant indicated which parent applications disclosed the particular peptides recited in the claims.
- 2. This application contains claims directed to the following patentably distinct species of the claimed invention:

The particular peptides recited in claim 1,14,26-29. Applicant needs to elect a particular peptide. It is noted that claim 20 reads on a peptide containing eight of the peptides recited in said claim (eg. wherein said eight peptides are linked). The elected peptide can be any one peptide encompassed by the aforementioned claims (eg. the elected peptide could be a peptide containing eight of the peptides recited in claim 20).

These peptides have different amino acid sequences.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

- 3. This application contains claims directed to the following patentably distinct species of the claimed invention:
 - a) a composition/vaccine containing a HTL epitope
 - b) a composition/vaccine containing a CTL epitope
 - c) a composition/vaccine containing a liposome
 - d) a composition/vaccine containing a lipidized peptide
 - e) a composition/vaccine containing a heteropolymer
 - f) a composition/vaccine containing a homopolymer
 - g) a composition/vaccine containing a peptide bound to a APC
 - h) a composition/vaccine containing a peptide bound to a tetramer

These compositions are functionally distinct and contain molecules that are chemically distinct.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Serial No. 09/583200 Art Unit 1644

4. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.
- 8. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may

be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ms Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Ron Schwadron, Ph.D.

Primary Examiner

Art Unit 1644

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1990 (600